Aiforia closes a deal with the Nantes University Hospital in France

Aiforia Technologies Plc, Press Release, May 19, 2025 at 11:00a.m. EEST

The Nantes University Hospital in France has selected Aiforia Technologies Plc as a partner for AI-assisted diagnostics in pathology. The collaboration will start with implementing selected Aiforia's Clinical AI solutions to the digital pathology workflow of the hospital. The agreement is signed for two years.

“We are excited to announce another clinical partnership in France. Public investments for the use of AI in healthcare are rapidly advancing the use of AI in digital pathology in France. Following our successful partnership in France with AP-HP hospital center in Paris, which was a strategically important market opening for Aiforia, this new collaboration demonstrates the strong adoption of Aiforia's AI solutions in the digitalization of healthcare and in improving the efficiency and accuracy of pathology image analysis in France,” says Jukka Tapaninen, CEO of Aiforia.

Nantes University Hospital, the 6th largest in France, is a top 10 university hospital, highly recognized for its research commitment. With its nine facilities, the Nantes University Hospital provides routine, local care to the 800,000 residents of the Nantes/Saint-Nazaire metropolitan area.

“Also, this partnership with the Nantes University Hospital marks an important achievement in our company's European expansion and strengthens our dedication to providing innovative solutions and exceptional value to our customers. We are also delighted that we can again provide a solution that helps the customer to enhance their diagnostic workflows,” says Jukka Tapaninen, CEO of Aiforia.

Further inquiries
Jukka Tapaninen, CEO, Aiforia Technologies Plc
tel. +33 61 041 6686
https://investors.aiforia.com/

Certified Adviser
UB Corporate Finance Ltd
ubcf@unitedbankers.fi

About Aiforia

Aiforia is a trusted provider of deep learning artificial intelligence (AI) solutions for pathology. Aiforia delivers software solutions that elevate diagnostic capabilities in image analysis, enabling remarkable medical discoveries now and in the future. With thousands of AI models already developed on the Aiforia platform for research use and several diagnostic solutions deployed, Aiforia is already significantly impacting pathology and healthcare.

Founded in 2013, Aiforia is a publicly traded company operating internationally with thousands of platform users across the globe. The company is headquartered in Helsinki, Finland, with offices in Cambridge, Massachusetts, and Rochester, Minnesota, and local representatives across Europe and North America. The diverse team at Aiforia includes experienced pathologists, medical scientists, AI and software developers, and a dedicated commercial team. Together, they are working to transform pathology with AI, enabling better care for each patient. Find out more at www.aiforia.com